Click here to get full coverage on Responsive Playbooks and the IMVT Inflection - Stock Traders Daily

Responsive Playbooks and the IMVT Inflection  Stock Traders Daily

Responsive Playbooks and the IMVT Inflection - Stock Traders Daily

Click here to get full coverage on Assessing Immunovant (IMVT) Valuation After Recent Share Price Weakness - Yahoo Finance

Assessing Immunovant (IMVT) Valuation After Recent Share Price Weakness  Yahoo Finance

Assessing Immunovant (IMVT) Valuation After Recent Share Price Weakness - Yahoo Finance

Click here to get full coverage on LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT  MSN

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

Click here to get full coverage on How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st

How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones  simplywall.st

How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st

Click here to get full coverage on Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - investing.com

Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m  investing.com

Roivant Sciences buys Immunovant (IMVT) shares worth $349.9m - investing.com

Click here to get full coverage on Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan

Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes  Stock Titan

Immunovant, Inc. (IMVT) CLO sells 2,877 shares to cover RSU taxes - Stock Titan

Click here to get full coverage on How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Zacks Investment Research

How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%  Zacks Investment Research

How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39% - Zacks Investment Research

Click here to get full coverage on IMMUNOVANT Earnings Results: $IMVT Reports Quarterly Earnings - Quiver Quantitative

IMMUNOVANT Earnings Results: $IMVT Reports Quarterly Earnings  Quiver Quantitative

IMMUNOVANT Earnings Results: $IMVT Reports Quarterly Earnings - Quiver Quantitative

Click here to get full coverage on A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance

A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway  Yahoo Finance

A Look At Immunovant (IMVT) Valuation After Trial Progress Updates And Extended Cash Runway - Yahoo Finance

Click here to get full coverage on Immunovant (IMVT) Valuation After IMVT-1402 Trial Enrollment Milestone And US$550 Million Capital Raise - simplywall.st

Immunovant (IMVT) Valuation After IMVT-1402 Trial Enrollment Milestone And US$550 Million Capital Raise  simplywall.st

Immunovant (IMVT) Valuation After IMVT-1402 Trial Enrollment Milestone And US$550 Million Capital Raise - simplywall.st

Click here to get full coverage on Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? - Yahoo Finance

Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed?  Yahoo Finance

Immunovant (IMVT) Is Up 14.0% After Roivant-Backed $550 Million Equity Raise For IMVT-1402 - Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update - Yahoo Finance

Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update  Yahoo Finance

Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update - Yahoo Finance

Click here to get full coverage on Where is Immunovant (IMVT) Heading According to Analysts? - Yahoo Finance

Where is Immunovant (IMVT) Heading According to Analysts?  Yahoo Finance

Where is Immunovant (IMVT) Heading According to Analysts? - Yahoo Finance

Click here to get full coverage on Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling - Yahoo Finance

Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling  Yahoo Finance

Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling - Yahoo Finance

Click here to get full coverage on IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Yahoo Finance

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus  Yahoo Finance

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Yahoo Finance

Click here to get full coverage on Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Yahoo Finance

Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation?  Yahoo Finance

Evaluating Immunovant (IMVT): Does Recent Momentum Signal a Premium Valuation? - Yahoo Finance

Click here to get full coverage on Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound?  Yahoo Finance

Immunovant (IMVT) Down 0.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Click here to get full coverage on Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance

Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple  Yahoo Finance

Is Immunovant (IMVT) Overvalued? Taking Stock of Its Premium Price-to-Book Multiple - Yahoo Finance

Click here to get full coverage on Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance

Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum  Yahoo Finance

Assessing Immunovant (IMVT) Valuation After Strong 90 Day Share Price Momentum - Yahoo Finance

Click here to get full coverage on Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - marketbeat.com

Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares  marketbeat.com

Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 2,877 Shares - marketbeat.com

Click here to get full coverage on Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - Yahoo Finance

Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings  Yahoo Finance

Oppenheimer Maintains Outperform Rating on Immunovant (IMVT) Following Q2 2026 Earnings - Yahoo Finance

Click here to get full coverage on Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position - marketbeat.com

Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position  marketbeat.com

Immunovant, Inc. $IMVT is Alpine Global Management LLC's 3rd Largest Position - marketbeat.com

Click here to get full coverage on HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT - marketbeat.com

HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT  marketbeat.com

HighVista Strategies LLC Grows Position in Immunovant, Inc. $IMVT - marketbeat.com

Click here to get full coverage on SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)  PR Newswire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT) - PR Newswire

Click here to get full coverage on JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - Yahoo Finance

JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37  Yahoo Finance

JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37 - Yahoo Finance

Click here to get full coverage on Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com - Investing.com South Africa

Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com  Investing.com South Africa

Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock By Investing.com - Investing.com South Africa

Click here to get full coverage on Understanding the Setup: (IMVT) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (IMVT) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (IMVT) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement  Seeking Alpha

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha

Click here to get full coverage on Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein - marketbeat.com

Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein  marketbeat.com

Immunovant (NASDAQ:IMVT) Now Covered by Sanford C. Bernstein - marketbeat.com

Click here to get full coverage on Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha

Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT)  Seeking Alpha

Immunovant: Takeover Buzz, IMVT-1402 Promise, And Why I'm Staying Neutral (NASDAQ:IMVT) - Seeking Alpha

Click here to get full coverage on Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT - marketbeat.com

Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT  marketbeat.com

Prosight Management LP Has $11.26 Million Stock Position in Immunovant, Inc. $IMVT - marketbeat.com

Click here to get full coverage on Immunovant (IMVT) Highlights New Graves’ Disease Data Can Its Pipeline Deliver Sustainable Innovation? - Yahoo Finance

Immunovant (IMVT) Highlights New Graves’ Disease Data Can Its Pipeline Deliver Sustainable Innovation?  Yahoo Finance

Immunovant (IMVT) Highlights New Graves’ Disease Data Can Its Pipeline Deliver Sustainable Innovation? - Yahoo Finance

Click here to get full coverage on The Technical Signals Behind (IMVT) That Institutions Follow - Stock Traders Daily

The Technical Signals Behind (IMVT) That Institutions Follow  Stock Traders Daily

The Technical Signals Behind (IMVT) That Institutions Follow - Stock Traders Daily

Click here to get full coverage on Immunovant CTO Stout sells $32k in IMVT stock - investing.com

Immunovant CTO Stout sells $32k in IMVT stock  investing.com

Immunovant CTO Stout sells $32k in IMVT stock - investing.com

Click here to get full coverage on Immunovant (NASDAQ: IMVT) sets second-quarter results Nov 10, update at 8:00 a.m. ET - Stock Titan

Immunovant (NASDAQ: IMVT) sets second-quarter results Nov 10, update at 8:00 a.m. ET  Stock Titan

Immunovant (NASDAQ: IMVT) sets second-quarter results Nov 10, update at 8:00 a.m. ET - Stock Titan

Click here to get full coverage on Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage  FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Click here to get full coverage on Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT - marketbeat.com

Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT  marketbeat.com

Citigroup Inc. Sells 75,860 Shares of Immunovant, Inc. $IMVT - marketbeat.com

Click here to get full coverage on Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - The Motley Fool

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish  The Motley Fool

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish - The Motley Fool

Click here to get full coverage on Precision Trading with Immunovant Inc. (IMVT) Risk Zones - Stock Traders Daily

Precision Trading with Immunovant Inc. (IMVT) Risk Zones  Stock Traders Daily

Precision Trading with Immunovant Inc. (IMVT) Risk Zones - Stock Traders Daily

Click here to get full coverage on Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT - marketbeat.com

Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT  marketbeat.com

Vanguard Group Inc. Has $110.05 Million Holdings in Immunovant, Inc. $IMVT - marketbeat.com

Click here to get full coverage on Roivant Unveils Remarkable Graves’ Disease Remission Data - The Clinical Trial Vanguard

Roivant Unveils Remarkable Graves’ Disease Remission Data  The Clinical Trial Vanguard

Roivant Unveils Remarkable Graves’ Disease Remission Data - The Clinical Trial Vanguard

Click here to get full coverage on Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet

Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones  AlphaStreet

Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet

Click here to get full coverage on TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT - marketbeat.com

TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT  marketbeat.com

TD Asset Management Inc Sells 56,752 Shares of Immunovant, Inc. $IMVT - marketbeat.com

Click here to get full coverage on Immunovant to Report Q2 Financial Results and Provide Business Update on November 10, 2025 - Quiver Quantitative

Immunovant to Report Q2 Financial Results and Provide Business Update on November 10, 2025  Quiver Quantitative

Immunovant to Report Q2 Financial Results and Provide Business Update on November 10, 2025 - Quiver Quantitative

Click here to get full coverage on Immunovant announces $550 million stock offering and clinical program updates - investing.com

Immunovant announces $550 million stock offering and clinical program updates  investing.com

Immunovant announces $550 million stock offering and clinical program updates - investing.com

Click here to get full coverage on Immunovant (IMVT) Gets a Buy from Oppenheimer - The Globe and Mail

Immunovant (IMVT) Gets a Buy from Oppenheimer  The Globe and Mail

Immunovant (IMVT) Gets a Buy from Oppenheimer - The Globe and Mail

Click here to get full coverage on We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely - simplywall.st

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely  simplywall.st

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely - simplywall.st

Click here to get full coverage on IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT - Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT  Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT - Business Wire

Click here to get full coverage on Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com Canada

Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock  Investing.com Canada

Immunovant (IMVT): Chief legal officer Van Tuyl sells $71k in stock - Investing.com Canada

Click here to get full coverage on Immunovant Announces $550 Million Stock Offering - TradingView

Immunovant Announces $550 Million Stock Offering  TradingView

Immunovant Announces $550 Million Stock Offering - TradingView

Click here to get full coverage on Immunovant Stock Surges 17% in 3 Months: What's Driving It? - The Globe and Mail

Immunovant Stock Surges 17% in 3 Months: What's Driving It?  The Globe and Mail

Immunovant Stock Surges 17% in 3 Months: What's Driving It? - The Globe and Mail

Click here to get full coverage on Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy | IMVT Stock News - Quiver Quantitative

Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy | IMVT Stock News  Quiver Quantitative

Immunovant Announces Promising Six-Month Follow-Up Data for Batoclimab in Uncontrolled Graves’ Disease Patients, Potentially Disease-Modifying Therapy | IMVT Stock News - Quiver Quantitative

Click here to get full coverage on Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV)  Seeking Alpha

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha

Click here to get full coverage on Bernstein Initiates Immunovant(IMVT.US) With Hold Rating, Announces Target Price $28 - 富途牛牛

Bernstein Initiates Immunovant(IMVT.US) With Hold Rating, Announces Target Price $28  富途牛牛

Bernstein Initiates Immunovant(IMVT.US) With Hold Rating, Announces Target Price $28 - 富途牛牛

Click here to get full coverage on IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3 - TradingView

IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3  TradingView

IMVT: Brepocitinib delivered strong phase 2 efficacy in cutaneous sarcoidosis, advancing to phase 3 - TradingView

Click here to get full coverage on (IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

(IMVT) Price Dynamics and Execution-Aware Positioning  Stock Traders Daily

(IMVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Click here to get full coverage on Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus - TechStock²

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus  TechStock²

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus - TechStock²

Click here to get full coverage on Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView

Immunovant Announces Pricing Of $550 Million Common Stock Financing  TradingView

Immunovant Announces Pricing Of $550 Million Common Stock Financing - TradingView

Click here to get full coverage on Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential - investing.com

Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential  investing.com

Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential - investing.com

Click here to get full coverage on Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?  The Motley Fool

Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million? - The Motley Fool

Click here to get full coverage on Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech

Batoclimab data in Graves’ could signal bigger Immunovant win  BioWorld MedTech

Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech

Click here to get full coverage on Roivant highlights continued pipeline progress and outlook - The Pharma Letter

Roivant highlights continued pipeline progress and outlook  The Pharma Letter

Roivant highlights continued pipeline progress and outlook - The Pharma Letter

Click here to get full coverage on IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm  Business Wire

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire

Click here to get full coverage on Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 247wallst.com

Share Offerings Prompt Huge Insider Buying in These 3 Biotechs  247wallst.com

Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 247wallst.com

Click here to get full coverage on Stocks With Rising Relative Strength: Immunovant - Investor's Business Daily

Stocks With Rising Relative Strength: Immunovant  Investor's Business Daily

Stocks With Rising Relative Strength: Immunovant - Investor's Business Daily

Click here to get full coverage on Immunovant gains amid takeover speculation - MSN

Immunovant gains amid takeover speculation  MSN

Immunovant gains amid takeover speculation - MSN

Click here to get full coverage on Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Disease News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer  Sjogren's Disease News

IMVT

Price Chart

Key Statistics

Technicals

About IMVT

Latest News

Responsive Playbooks and the IMVT Inflection - Stock Traders Daily

Assessing Immunovant (IMVT) Valuation After Recent Share Price Weakness - Yahoo Finance

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

Advanced Charts

Top Gainers

Top Losers